Loading...
•
Jun 30, 2022
Balchem Q2 2022 Earnings Report
Balchem's second quarter performance in 2022 was marked by record sales and adjusted EBITDA, driven by growth across all segments and strategic acquisitions.
Key Takeaways
Balchem Corporation reported a strong second quarter in 2022, with record net sales of $236.7 million and net earnings of $29.8 million. The company's performance was driven by growth in all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Balchem also completed the acquisition of Kappa Bioscience AS, expanding its presence in the human nutrition industry.
Record net sales of $236.7 million, a 17.0% increase compared to the prior year quarter.
GAAP net earnings were $29.8 million, a 31.0% increase from the prior year.
Adjusted EBITDA reached a record $56.5 million, a 12.6% increase from the prior year.
Completed the acquisition of Kappa Bioscience AS on June 21, 2022.
Balchem
Balchem
Balchem Revenue by Segment
Revenue by Segment
Human Nutrition & Health Revenue
CapyFin.comAnimal Nutrition & Health Revenue
CapyFin.comSpecialty Products Revenue
CapyFin.com Forward Guidance
The second quarter of 2022 was another excellent quarter for Balchem. We delivered very strong financial results, despite ongoing macro-economic challenges. The Balchem team continues to respond extremely well to the ongoing supply chain, workforce availability, and inflationary challenges. Our ability to deliver these strong financial results while managing through these challenges, is a great testament to the resilience and strength of our business model as well as the incredible dedication and capabilities of the Balchem team.
Positive Outlook
- The second quarter of 2022 was another excellent quarter for Balchem.
- We delivered very strong financial results, despite ongoing macro-economic challenges.
- The Balchem team continues to respond extremely well to the ongoing supply chain, workforce availability, and inflationary challenges.
- Our ability to deliver these strong financial results while managing through these challenges, is a great testament to the resilience and strength of our business model as well as the incredible dedication and capabilities of the Balchem team.
- We are very excited about the recent acquisition of Kappa Biosciences and the strength it brings to our company and I would like to, once again, welcome the Kappa team to the broader Balchem team!
Revenue & Expenses
Visualization of income flow from segment revenue to net income